Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 645.64

+2.8%

3:53 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (336)	12/11/1999 7:48:00 PM
From: Pseudo Biologist	Read Replies (1) of 3557

Miljenko, thank you thank you for sharing this analysis. You make a good case for the limited downside, which I gather comes from (a)potential revenues from manufacturing capacity, and (b) high probability of BDNF's at least modest success in ALS. Without knowing nearly enough facts, I have to say that the most recent data from Axokine do not give me a whole lot of confidence. I share your admiration for the scientific approach of Yancopoulos and team. Amazing depth and range. Not clear when one will see more indication of the accumulated knowledge translating into a winning clinical strategy, however. Then again, one can say that this is MLNM/HGSI/etc with less tech and more brain, and therefore worth quite a bit more than what the market is saying. Did I miss your thoughts on NT3? PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next